X

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Immunogenicity and Anti-Tumour Activity of BIL06v/Alhydrogel in Patients with Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BIL 06v (Primary) ; Aluminium hydroxide
Indications Solid tumours
Focus Adverse reactions; Pharmacodynamics
Sponsors Biosceptre International

Most Recent Events

11 Dec 2020 Status changed from active, no longer recruiting to completed.
30 Aug 2019 Status changed from recruiting to active, no longer recruiting.
21 Aug 2018 According to a Biosceptre International media release, the first patients has been treated in this study at the Sydney Adventist Hospital in Sydney on 16th Aug 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com